Full Press Release Details
Shares CGuardTM EPS Video Testimonials
from European Key Opinion Leaders
Aviv-August 22, 2017 - InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) ("InspireMD" or the "Company"),
a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it
has posted video testimonials about its CGuardTM Embolic Prevention System from several European key opinion leaders
on its website: http://www.inspiremd.com/en/kol-testimonials/
testimonials include:
| Dr. Alberto Cremonesi, Chief of the Cardiovascular Department at Maria Cecilia Hospital, Cotignola, Italy | ||
| Dr. Antonio Moreno, Chief Medical Officer of Endovascular Intervention World MEDICA, Madrid, Spain | ||
| Dr. Bernhard Reimers, Clinical and Invasive Cardiology Unit Director at Humanitas Research Hospital, Milan, Italy | ||
| Prof. Ralf Kolvenbach, Head of the Cardiovascular Diseases Department, Medical Director of the Catholic Hospitals, Duesseldorf, Germany | ||
| Prof. Piotr Musialek, Jagiellonian University Department of Cardiac & Vascular Diseases, Krakow, Poland |
Barry, PhD, Chief Executive Officer of InspireMD, commented, "We are honored that such respected clinicians from the fields
of vascular surgery, interventional cardiology and interventional neuroradiology across Europe are willing to publicly endorse
our very promising technology. These testimonials provide detailed and diverse clinical views on the advantages of the CGuard
Embolic Prevention System, as described by those who use it routinely in their daily practices to improve patient outcomes."
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard ), neurovascular, and peripheral
artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants
are quoted on the NYSE American under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.